Our website have detected that you are using an outdated browser that will prevent you from accessing certain features. klikk for mer informasjon.
Cart
Handlekurv

INVESTORRELASJONER

Her finner du informasjon på engelsk som gir deg oversikt over Zinzinos økonomiske resultat, samt strategisk retning fremover.


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT APRIL 2021

Strong sales growth during April; Zinzino group revenue increased with a total of 21%, compared with the previous year. The revenue in April for Zinzino's sales markets increased by 17% to SEK 98.7 (84.2) million due to strong growth in several regions. Faun Pharma's external sales increased by 97% and amounted to SEK 7.5 (3.8) million. Overall, the Group increased revenues by 21% to SEK 106.2 (88.0) million compared with the previous year. Accumulated revenue for January – April 2021 increased by 33% SEK 439.7 (330.2) million. Revenues were distributed as follows: Regions,MSEK Les mer »

Published: 4 mai Last ned PDF


ANNUAL REPORT ENGLISH 2020 ZINZINO AB (PUBL)

Zinzino (publ) announces that the Annual Report for 2020 is now published in Swedish at the company’s website, zinzino.com. An English version will be published within 45 days.  https://zinzinowebstorage.blob.core.windows.net/financialdocuments/Zinzino-arsredovisning-2020.pdf Zinzino will hold the Annual General Meeting on Thursday May 20th, 2021. Taking into account the health of both the shareholders and the company representatives as well as ongoing efforts to limit the spread of infection, the Annual General Meeting will be held without the possibility of physical participation. Les mer »

Published: 28 apr Last ned PDF


NOTICE OF THE ANNUAL GENERAL MEETING OF ZINZINO AB (publ.)

The shareholders of Zinzino AB (publ), org. no. 556733-1045 (the “Company”) are hereby invited to participate in the Annual General Meeting on Thursday, 20 May 2021. 2021 ANNUAL GENERAL MEETING FORMAT In light of the extraordinary situation society finds itself in due to coronavirus, the format of the 2021 Annual General Meeting of Zinzino AB will be adapted accordingly. Taking into account the health of both the shareholders and the company representatives as well as ongoing efforts to limit the spread of infection, the Annual General Meeting will be held without the possibility of Les mer »

Published: 21 apr Last ned PDF


ZINZINO AB (PUBL): A new signature BalanceOil from the pioneers of test-based nutrition

The global, Scandinavian health and wellness brand is taking the next step in its ambition to shape the future of nutrition with test-based, scientifically proven supplements. BalanceOil+ Premium with its unparalleled supply of polyphenols and phytonutrients is the D2C company’s latest addition to their range of BalanceOils restoring Omega levels and protecting the cells from oxidative stress. In this premium version, Zinzino’s exceptional and innovative blend of natural fish oil and vitamin D3 also includes a scientifically certified measure of R.E.V.O.O; the company’s private label of Les mer »

Published: 15 apr Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q1 2021

Strong sales growth during Q1; Zinzino group revenue increased with a total of 37%. The revenue in March for Zinzino's sales markets increased by 56% to SEK 120.6 (77.4) million due to strong growth in several regions. Faun Pharma's external sales increased by 86% and amounted to SEK 5.2 (2.8) million. Overall, the Group increased revenues by 57% to SEK 125.8 (80.2) million compared with the previous year. The Zinzino based revenue in January – March increased 38% MSEK 315.1 (228.7) million compared with previous year. Total group revenue increased 37% to SEK 332,4 (242,1) million. Les mer »

Published: 7 apr Last ned PDF


ZINZINO AB (PUBL): Zinzino announces the launch of India as next step in their global expansion strategy

Zinzino is very proud to announce the launch of India as the company’s next step in their global expansion strategy. After several years of preparing the launch of the Indian market and having carried out multiple country establishment processes in recent years, the company has learned the importance of ensuring thorough preparatory work and adapting to the local conditions in each market.Profitable growth is an important business strategy for the e-commerce-based health tech company Zinzino. During 2020 the company sales target was exceeded by an excellent sales growth and a strong EBITA Les mer »

Published: 6 apr Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2021

Strong sales growth during February; Zinzino group revenue increased with a total of 33%, compared with the previous year. The revenue in February for Zinzino's sales markets increased by 30% to SEK 94.4 (72.5) million due to strong growth in several regions. Faun Pharma's external sales increased by 81% and amounted to SEK 6.7 (3.7) million. Overall, the Group increased revenues by 33% to SEK 101.1 (76.2) million compared with the previous year. Accumulated revenue for January – February 2021 increased by 29% SEK 208.1 (161.9) million. Revenues were distributed as follows: Regions, Les mer »

Published: 3 mar Last ned PDF


ZINZINO AB (PUBL): YEAR-END REPORT 2020

INCREASED SHARE DIVIDEND AFTER RECORD CLOSING OF THE YEAR The fourth quarter of 2020 was the strongest quarter ever in the Company’s history regarding sales. Total revenues in the Group increased by 44% and amounted to SEK 340.4 (236.3) million. This is due to sales growth in all regions. The strongest growth continued to be found in the Central European countries, but Asia and North America also increased significantly during the quarter. Profitability was also very good and the EBITDA result amounted to SEK 37.4 (6.3) million for the quarter. The EBITDA margin amounted to the record Les mer »

Published: 26 feb Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JANUARY 2021

Solid sales growth during January; Zinzino group revenue increased with a total of 26%, compared with the previous year. The revenue in January for Zinzino's sales markets increased by 30% to SEK 102.3 (78.7) million due to strong growth in several regions. Faun Pharma's external sales decreased by 23% and amounted to SEK 5.3 (6.9) million. Overall, the Group increased revenues by 26% to SEK 107.6 (85.6) million compared with the previous year. Revenues distributed as follows: Regions,MSEK 21-jan 20-jan Change YTD 2021 YTD 2020 Change The Nordics 33.0 33.0 Les mer »

Published: 3 feb Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT 2020

Strong sales growth during 2020; Zinzino group revenue increased with a total of 44% in Q4 and 48% for the full year 2020, compared with the previous year. The revenue in December for Zinzino's sales markets increased by 77% to SEK 127.9 (72.3) million due to strong growth in many regions and countries. Faun Pharma's external sales increased by 158% and amounted to SEK 6.2 (2.4) million. Overall, the Group increased revenues by 80% to SEK 134.1 (74.7) million compared with the previous year. The fourth quarter of 2020 became the strongest quarter in the history of the company. The Zinzino Les mer »

Published: 7 jan Last ned PDF


ZINZINO AB (PUBL): Further expansions of the Zinzino global web shop

Zinzino is very proud to announce the launch of a global web shop for distributors in more than 60 countries who may now start operating under the Zinzino flag. This is an approach that reduces the pressure to open full-scale markets, which requires a lot of attention from the organisation. In tandem with the launch of the global web shop, the establishment processes continue in several markets including the Asian markets that have all become available through the acquisition of VMA Life. Having carried out multiple establishment processes in recent years, the company has learned the Les mer »

Published: 15 des Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT NOVEMBER 2020

Solid sales growth during November; Zinzino group revenue increased with a total of 36%, compared with the previous year. The revenue in November for Zinzino's sales markets increased by 35% to SEK 93.7 (69.3) million primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 48% and amounted to SEK 4.3 (2.9) million. Overall, the Group increased revenues by 36% to SEK 98.0 (72.2) million compared with the previous year. During the last days of November Zinzino’s Black Friday campaign was carried out with a very successful outcome, and a Les mer »

Published: 3 des Last ned PDF


ZINZINO AB (PUBL): INTERIM REPORT THIRD QUARTER 2020

HISTORICAL ALL-TIME HIGH FOR ZINZINO – WE’RE INCREASING THE PROFIT FORECAST SIGNIFICANTLY The third quarter 2020 was the strongest quarter in the company’s history in terms of sales. Total revenues in the Group increased by 51% and amounted to SEK 281.8 (186.5) million. This is due to sales growth in all regions. The strongest growth continued to be in the Central European countries, but North America also increased significantly during the quarter. Profitability was also very good and the EBITDA result amounted to SEK 28.8 (4.4) million for the quarter. The EBITDA margin consequently Les mer »

Published: 20 nov Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT OCTOBER 2020

Solid sales growth during October; Zinzino group revenue increased with a total of 21%, compared with the previous year. The revenue in October for Zinzino's sales markets increased by 18% to SEK 100.8 (85.1) million primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 63% and amounted to SEK 7.0 (4.3) million. Overall, the Group increased revenues by 21% to SEK 107.8 (89.4) million compared with the previous year. Accumulated revenue for January – October 2020 increased by 45% SEK 906.1 (623.2) million. Revenues distributed as follows: Les mer »

Published: 3 nov Last ned PDF


ZINZINO AB (PUBL): Zinzino Hong Kong launch

Zinzino is very proud to announce the launch of Hong Kong as the first Zinzino market to be opened as new business in Asia. Hong Kong is a strategic important market for Zinzino Asia to achieve solid growth rates in the foreseen future. “We expect a lot from the Asian market and this is the reason why we acquired VMA Life with direct selling operations in Hong Kong, Thailand, Taiwan, Singapore and Malaysia end of 2019. This is truly exciting and we are ready to begin a new chapter in our company”, says CEO Dag Bergheim Pettersen. Zinzino is a direct selling company with a focus on Les mer »

Published: 8 okt Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q3 2020

Strong sales growth during Q3; Zinzino group revenue increased with a total of 49% in Q3 and 49% YTD, compared with the previous year. The revenue in September for Zinzino's sales markets increased by 64% to SEK 98.1 (60.0) million primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 32% and amounted to SEK 5.4 (4.1) million. Overall, the Group increased revenues by 61% to SEK 103.5 (64.1) million compared with the previous year. The third quarter of 2020 became the strongest quarter in the history of the company. The Zinzino based revenue Les mer »

Published: 5 okt Last ned PDF


ZINZINO AB (PUBL): ZINZINO MOVES TO THE PREMIER SEGMENT OF FIRST NORTH GROWTH MARKET

Zinzino AB (publ) announces today that Nasdaq has approved the Company’s application to move its stock trading to First North Premier Growth Market. The transfer is an important step towards a future listing on Nasdaq’s main market. The trade in Zinzino’s shares on First North Premier Growth Market will be initiated on Monday, September 21, 2020. “The fact that we are able to move the trade to Premier is an important strategic step in our global expansion, and facilitates institutional and international ownership of Zinzino”, says Dag Bergheim Pettersen, CEO. The Premier segment of First Les mer »

Published: 16 sep Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT AUGUST 2020

Strong sales growth during August: Zinzino group revenue increased with a total of 45%, compared with the previous year. The revenue in August for Zinzino's sales markets increased by 50% to MSEK 82.0 (54.7) primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 19% and amounted to MSEK 3.4 (4.2). Overall, the Group increased revenues by 45% to MSEK 85.4 (58.9) compared with the previous year. Accumulated revenue for January – August 2020 increased by 47% MSEK 690.9 (469.7). Revenues distributed as follows: Regions,MSEK 20-aug Les mer »

Published: 7 sep Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT SECOND QUARTER 2020

ANOTHER RECORD-SETTING QUARTER FOR ZINZINO – THE COMPANY IS INCREASING THE FORECAST FOR 2020 Strong growth in Central Europe combined with good development on most other markets contributed to total revenues increasing by 53% to SEK 274.3 (179.5) million during the second quarter. During the quarter, Zinzino continued to adapt and optimize operations to maintain the good sales growth during the pandemic outbreak. The outcome has been favorable, which means that the company adjusts the sales forecast for 2020 by SEK 100 million to SEK 1,100 million. To achieve more efficient shipments to Les mer »

Published: 28 aug Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JULY 2020

Strong sales growth during July; Zinzino group revenue increased with a total of 44%, compared with the previous year. The revenue in July for Zinzino's sales markets increased by 45% to MSEK 87.5 (60.3) primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 21% and amounted to MSEK 4.0 (3.3). Overall, the Group increased revenues by 44% to MSEK 91.5 (63.6) compared with the previous year. Accumulated revenue for January–July 2020 increased by 48% MSEK 607.9 (410.9). Revenues distributed as follows: +--------------------+-------+-------+- Les mer »

Published: 5 aug Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q2 2020

Strong sales growth during Q2; Zinzino group revenue increased with a total of 53% in Q2 and 49% YTD, compared with the previous year. The revenue in June for Zinzino's sales markets increased by 77% to MSEK 94.9 (53.7) primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales increased by 15% and amounted to MSEK 5.3 (4.6). Overall, the Group increased revenues by 72% to MSEK 100.2 (58.3) compared with the previous year. The second quarter of 2020 became the strongest quarter in the history of the company. The Zinzino based revenue in April - June increased Les mer »

Published: 6 jul Last ned PDF


ANNUAL REPORT ENGLISH 2019 ZINZINO AB (PUBL)

Zinzino (publ) announces that the Annual Report for 2019 is now available for download in English at the company’s website, www.zinzino.com.   For more information: Fredrik Nielsen, CFO Zinzino + 46 (0) 707 900 174, zinzino.com Pictures for publication free of charge: Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollblom@zinzino.com Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se   Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Les mer »

Published: 9 jun Last ned PDF


ZINZINO AB (PUBL): PRELIMINARY SALES REPORT MAY 2020

Strong sales growth during May; Zinzino group revenue increased with a total of 31%, compared with the previous year. The revenue in May for Zinzino's sales markets increased by 34% to MSEK 80.5 (60.2) primarily due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 5% and amounted to MSEK 3.5 (3.7) due to high level of internal production. Overall, the Group increased revenues by 31% to MSEK 84.0 (63.9) compared with the previous year. Accumulated revenue for January – May 2020 increased by 43% MSEK 414.2 (289.0). Revenues distributed as follows: Les mer »

Published: 2 jun Last ned PDF


ZINZINO AB (PUBL): INTERIM REPORT FIRST QUARTER 2020

CONTINUOUS STRONG GROWTH - DIVIDEND PROPOSAL REMAINS Strong growth in Central Europe combined with positive development in most other markets contributed to total revenues increasing with 44% to SEK 242.1 (168.3) million in the first quarter despite the outbreak of the global Covid-19 pandemic. Items affecting comparability regarding recognition of sales commissions of SEK 22.2 million improved the EBITDA profit, which amounted to 26.3 (11.9) and the EBITDA margin, which amounted to 10.9% (7.0%). Adjusted EBITDA was SEK 4.1 million and the adjusted EBITDA margin was 1.7%. The Board of Les mer »

Published: 14 mai Last ned PDF